Mr. Azelby joins Alder from
“We are thrilled to have Bob join Alder at this key stage in the company’s history. He is a seasoned leader who brings significant operational experience and a strong track record in both large and small biopharmaceutical environments, and his skills will be of great value as we progress our CGRP inhibitor, eptinezumab, towards approval and commercialization for migraine prevention,” said Mr. Cleveland. “We look forward to Bob’s leadership as we continue to deliver on our commitment to transform the treatment paradigm for migraine prevention to benefit the millions of underserved patients living with migraine and create value for our shareholders.”
“Eptinezumab has the potential to make a significant difference in the lives of people dealing with the debilitating effects of migraine,” Mr. Azelby said. “I am excited to join Alder at this pivotal time for both the company and the migraine community.”
Mr. Azelby brings over 26 years of biopharmaceutical industry expertise. Prior to joining Juno in 2015, Mr. Azelby had a 15-year career of building high-performing teams and creating strong value at
Mr. Azelby began his career in the industry as a sales representative in
Azelby holds a bachelor’s degree in economics and religious studies from the
This press release contains forward-looking statements, including, without limitation, statements relating to: Alder’s expectations regarding the appointment of Mr. Azelby; the continued development and clinical, therapeutic and commercial potential of eptinezumab; progress towards the approval and commercialization of eptinezumab; and Alder’s commitment to transform the treatment paradigm for migraine prevention and create value for shareholders. Words such as “will,” “towards,” “look forward,” “continue,” “deliver,” “commitment,” “create,” “potential,” or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Alder's current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption "Risk Factors" in Alder's Quarterly Report on Form 10-Q for the quarterly period ended
Investor Relations Contact:
Vice President, Corporate Strategy
Stern Investor Relations, Inc.
Source: Alder BioPharmaceuticals, Inc.